Author:Qingfeng Pharmaceutical Group
Posted Time:2024-09-07 00:00
On September 7, 2024, the 41st National Pharmaceutical Industry Information Annual Conference opened in Chengdu, Sichuan. At the conference, the Ministry of Industry and Information Technology released its highly anticipated 2023 “China's top 100 Pharmaceutical Industry”, with Qingfeng Pharmaceutical ranking 56th, up 24 spots from last year.
The National Pharmaceutical Industry Information Annual Conference is one of the most influential industry events in China’s pharmaceutical sector. This year’s conference, themed “Holding Fast, Embracing the New, and Shining for the Future,” calls on pharmaceutical professionals to stay true to their original intentions and social responsibilities in the face of unprecedented challenges and opportunities in China’s health industry, while relentlessly pursuing innovation, exploring new models for cooperation, and striving for a future of higher quality, efficiency, and standards.
The “China's top 100 Pharmaceutical Industry”, published at the conference, is one of the most authoritative and representative industry evaluations in China, highlighting the main development trends of the pharmaceutical industry in the near future. The selection and ranking of the China's Top 100 Pharmaceutical Industry undergoes a rigorous and standardized review process with seven rounds of evaluation. The results attract significant attention and recognition from the industry. Qingfeng Pharmaceutical’s inclusion in the “China's top 100 Pharmaceutical Industry” once again demonstrates the company’s position within the industry, and represents the industry’s recognition of the company’s contributions to innovation, industrial development, and social responsibility.
Differentiated Innovation Accelerates into the “Fast Lane”
In recent years, innovation in biomedicine has flourished, but excessive competition and me-too innovations have caused a significant waste of resources in the industry. Original innovation capabilities are still insufficient, and many clinical needs remain unmet At the same time, driven by policies, capital, clinical needs, and technology, the innovation ecosystem in the Chinese pharmaceutical industry is rapidly reshaping, with emerging technologies facilitating the upgrading and development of pharmaceutical products, propelling the industry’s evolution into the “fast lane.”
Amidst profound transformations in the pharmaceutical industry, Qingfeng Pharmaceutical has actively aligned itself with the Healthy China strategy, focusing on four key therapeutic fields: oncology, anti-infection, gastrointestinal system, and CNS. The company is steadfast in its differentiated competitive strategy, pursuing distinctive innovation and remaining dedicated to addressing unmet clinical needs. It aims to provide patients with high-quality, affordable medicines, showcasing the company’s strengths and sense of responsibility as one of the China's top 100 Pharmaceutical Industry.
Proactive Approach, Consistent Achievements
In 2023, Qingfeng Pharmaceutical obtained a total of 15 drug manufacturing approvals, setting a historic record. Of these, Enzalutamide API and soft capsules were approved for sale in the U.S., marking a key step in the company’s internationalization strategy. Aurantii® Fructus Immaturus Total Flavonoids Tablet, a 1.2-class innovative traditional Chinese medicine, was approved for market. It is the first medication of this type in the domestic gastrointestinal field in nearly a decade, and the world’s first natural gastrointestinal motility drug. The Chinese-developed small-molecule novel flu drug, Mashurashave (GP681), has had its market approval application accepted. It is expected to be approved in the first half of 2025, potentially leading the new generation of anti-infection drugs and becoming a leader in the rapidly evolving multi-billion-dollar flu drug market.
In 2024, despite numerous industry challenges, Qingfeng Pharmaceutical did not slow down its innovation efforts, but instead chose to take a proactive approach. By the end of August, 9 products had been approved for market. Among them, Eribulin Mesylate Injection was approved by the U.S. FDA. This is Qingfeng Pharmaceutical’s second product to be approved in the U.S. after Enzalutamide, making the company the second global and first Chinese pharmaceutical company to have this product approved for market in the U.S. Brivaracetam, a third-generation antiepileptic drug, was approved for market, filling a domestic gap. Perampanel Tablets were approved for market, marking Qingfeng Pharmaceutical’s breakthrough in the mental health drug category.
Over the past five years, Qingfeng Pharmaceutical has received more than 40 approvals for the production of high-end generic drugs. This includes 8 first-to-market or first-to-pass consistency evaluation products, and 11 products selected in national centralized procurement projects. These achievements have played a significant role in imported drug substitution and reducing the medical burden on patients.
Resilience Amidst the Downturn
The domestic pharmaceutical industry is currently in a counter-cyclical phase. To navigate through this cycle, resilience and sharpness are essential. Despite the volatile external environment, Qingfeng Pharmaceutical will continue to adhere to its principles of "Futurism," "Long-termism," and "Valueism." The company will focus on unmet clinical needs, maintain its strategic determination and patience, invest in R&D, and continue to craft high-quality medicines. Qingfeng is committed to providing affordable and effective treatments to patients around the world.
